Taspoglutide

Drug Profile

Taspoglutide

Alternative Names: BIM 51077; BM 51077; BN 51077; ITM-077; R1583; RG 1583

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Developer Roche; Teijin Pharma
  • Class Amino acids; Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 Jul 2011 Roche terminates a phase III trial in Type-2 diabetes mellitus (insulin-naive patients) in countries worldwide (NCT01051011)
  • 21 Apr 2011 Suspended - Phase-II for Type-2 diabetes mellitus in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top